NeuroSigma, a bioelectronics company based in Los Angeles, has announced the establishment of its first foreign subsidiary, NeuroSigma Pte, Ltd., in Singapore. The company specializes in using external trigeminal nerve stimulation (eTNS) technology to treat neurological and neuropsychiatric disorders. NeuroSigma’s lead product, the Monarch eTNS System, is the first non-pharmaceutical treatment for pediatric ADHD that has been cleared by the U.S. Food and Drug Administration (FDA).
The decision to establish a subsidiary in Singapore is part of NeuroSigma’s mission to bring its innovative bioelectronics therapies to the global patient marketplace. Singapore was chosen as the ideal launching point for Southeast Asia due to its business-friendly environment and support for the biotechnology industry. The company has already developed strong relationships with leading universities, hospitals, and government agencies in Singapore, including the Biomedical Sciences Industry Partnership Office (BMSIPO), a national platform under the Agency for Science, Technology and Research (A*STAR).
According to Colin Kealey, M.D., President and CEO of NeuroSigma, Singapore’s academic and scientific community offers access to world-leading experts and innovators in neuropsychiatry, neurostimulation, and neuroimaging. This makes Singapore an excellent base for launching NeuroSigma’s next-generation eTNS devices and conducting further research into devices and technologies that address significant unmet medical needs. The company is already engaging in discussions with local experts in the field for potential research collaborations.
NeuroSigma Singapore has secured initial seed funding from Checkmate Capital Group, marking the second investment this year by the group in a biotechnology enterprise based in Singapore. The company expects to initiate regulatory applications with the Singapore Health Sciences Authority to commercialize the Monarch eTNS system in Singapore later this year.
Tom Paschall, CEO of Checkmate Capital Group and a Director of NeuroSigma, expressed his confidence in Singapore’s support for biotechnology companies and its commitment to cutting-edge research and innovation. Paschall believes that positioning NeuroSigma’s Southeast Asia operations in Singapore will allow the company to expand its global footprint and accelerate the commercialization and sales of the Monarch eTNS System in Asia.
NeuroSigma is a Los Angeles-based bioelectronic medical device company that aims to transform medical practice and improve patients’ lives. Its flagship product, the Monarch eTNS System, is the first non-drug treatment for pediatric ADHD approved by the FDA. The company’s pipeline includes potential applications for the Monarch and its TNS platform in various neurological and neuropsychiatric disorders, such as drug-resistant epilepsy and depression.
For more information about NeuroSigma and its products, please visit their website at www.neurosigma.com. To learn more about the Monarch eTNS System specifically, visit www.monarch-etns.com.
